Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Viz.ai›
Analysis
AddedFeb 27, 2023
UpdatedJun 13, 2026
Viz.ai

Viz.ai

A platform that accelerates care coordination, from diagnosis to treatment for various conditions.

HQ
San Francisco, CA, US
Founded
2016
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Website
Relative Profitability
TEST

Contents

  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy
  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy

Product Overview

Viz.ai is a computational pathology company that offers a platform for rapid disease detection and treatment. The company's flagship product is Viz LVO, a cloud-based tool that utilizes artificial intelligence (AI) to analyze medical images and identify patients with large vessel occlusion (LVO) strokes. LVO strokes are a type of ischemic stroke, which occurs when a blood vessel in the brain becomes blocked by a clot.

Viz LVO works by analyzing computed tomography (CT) scans of the brain, which are commonly used to diagnose strokes. The software uses deep learning algorithms to analyze the images and detect signs of LVO strokes, such as blocked blood vessels. When an LVO stroke is detected, Viz LVO sends an alert to the stroke team, enabling them to quickly assess the patient and determine the appropriate course of treatment.

One of the key benefits of Viz LVO is its ability to save time in the stroke treatment process. Because LVO strokes require urgent treatment, every minute counts. Viz LVO can help reduce the time between stroke onset and treatment by quickly identifying LVO strokes and notifying the stroke team. This can help improve patient outcomes and reduce the risk of long-term disability or death.

In addition to Viz LVO, Viz.ai also offers a range of tools for disease detection and care coordination, specifically for aortic disease, pulmonary embolism, cerebral aneurysms, and subdural hematoma.

Competitive Advantages

Viz.ai has several advantages that differentiate it from its competitors in the computational pathology market, particularly in the field of stroke care. These advantages include:

Advanced AI technology: Viz.ai's platform is powered by advanced artificial intelligence (AI) algorithms that can quickly and accurately analyze medical images to detect signs of stroke. The company has invested heavily in developing its AI technology and has achieved impressive results in clinical trials, demonstrating high levels of accuracy and efficiency.

Rapid stroke detection and treatment: The company's flagship product, Viz LVO, is designed to help hospitals quickly detect and treat strokes, particularly large vessel occlusion (LVO) strokes, which require urgent treatment. By using AI to analyze medical images and alerting stroke teams in real-time, Viz.ai can help reduce the time between stroke onset and treatment, improving patient outcomes and reducing the risk of long-term disability or death.

Streamlined stroke care processes: In addition to its stroke detection platform, Viz.ai also offers a stroke triage and management platform that helps hospitals streamline their stroke care processes. The platform includes features such as automated alerts, patient tracking, and real-time data analytics, which can help improve communication and coordination among the stroke team and enable faster and more efficient stroke care.

Strong clinical evidence: Viz.ai has conducted several clinical trials to validate the effectiveness of its platform in detecting and treating strokes. The company has also published peer-reviewed studies demonstrating the clinical and economic benefits of its platform. This strong clinical evidence can help differentiate Viz.ai from its competitors and provide a compelling value proposition for hospitals and health systems.

Overall, Viz.ai's competitive advantages are its advanced AI technology, rapid stroke detection and treatment, streamlined stroke care processes, and strong clinical evidence position the company as a leader in the computational pathology market, particularly in the field of stroke care.

Competitive Disadvantages

While Viz.ai has several competitive advantages, there are also some potential challenges that the company may face, including:

Market competition: The computational pathology market is highly competitive, and Viz.ai faces competition from other companies offering similar AI-powered disease detection and management solutions. Some of these competitors may have more established market positions or larger marketing budgets, which could make it more difficult for Viz.ai to compete.

Data privacy and security concerns: Viz.ai's platform relies on the use of patient data, which raises concerns about data privacy and security. Hospitals and health systems may be hesitant to share patient data with Viz.ai or other third-party vendors, particularly if they do not have strong data privacy and security protocols in place.

Regulatory hurdles: As a healthcare technology company, Viz.ai must comply with a range of regulations and standards, such as HIPAA and FDA regulations. Compliance with these regulations can be complex and time-consuming, and failure to comply can result in penalties or legal action.

Overall, while Viz.ai has several competitive advantages that position it as a leader in the computational pathology market, the company may also face some potential challenges at it tries to gain market share, particularly in terms of market competition, data privacy and security concerns, and regulatory hurdles.

Pricing Strategy

Viz.ai’s product is a cloud-based software-as-a-service (SaaS) platform. This suggests that customers pay a recurring fee to access the platform, rather than purchasing a one-time license. The subscription fee may be based on factors such as the number of users, the volume of data processed, or the level of support provided.

Viz.ai's pricing strategy may also involve offering different pricing tiers or packages to meet the needs of different types of customers. For example, the company may offer a basic package with limited features and functionality for smaller hospitals or clinics, and a more advanced package with additional features and support for larger hospitals or health systems.

Overall, Viz.ai's pricing strategy appears to be designed to provide customers with flexibility and value, while also generating recurring revenue for the company.